To the Editor:The global prevalence of chronic spontaneous urticaria(CSU)is estimated to be approximately 0.5–1%,with approximately 0.75%in China.[1,2]Secondgeneration H1-antihistamines(H1AHs)at a standard dose are c...To the Editor:The global prevalence of chronic spontaneous urticaria(CSU)is estimated to be approximately 0.5–1%,with approximately 0.75%in China.[1,2]Secondgeneration H1-antihistamines(H1AHs)at a standard dose are currently the preferred first-line treatment for CSU.In the case of an inadequate response to H1AHs after 1–2 weeks of treatment,the dose of the same H1AH could be increased to a maximum of 4-fold,or it could be combined with other antihistamines.For patients with CSU who remain intolerant or unresponsive despite 2–4 weeks of treatment with increased doses of antihistamines,omalizumab,a humanized recombinant anti-immunoglobulin E(IgE)monoclonal antibody(300 mg every 4 weeks),is recommended as third-line treatment.[3]展开更多
文摘To the Editor:The global prevalence of chronic spontaneous urticaria(CSU)is estimated to be approximately 0.5–1%,with approximately 0.75%in China.[1,2]Secondgeneration H1-antihistamines(H1AHs)at a standard dose are currently the preferred first-line treatment for CSU.In the case of an inadequate response to H1AHs after 1–2 weeks of treatment,the dose of the same H1AH could be increased to a maximum of 4-fold,or it could be combined with other antihistamines.For patients with CSU who remain intolerant or unresponsive despite 2–4 weeks of treatment with increased doses of antihistamines,omalizumab,a humanized recombinant anti-immunoglobulin E(IgE)monoclonal antibody(300 mg every 4 weeks),is recommended as third-line treatment.[3]
